Editas Medicine (EDIT) Short term Debt (2024 - 2025)
Editas Medicine's (EDIT) quarterly Short term Debt came in at $5.0 million in Q4 2025, little changed year-on-year from $5.0 million in Q4 2024, and little changed on a QoQ basis from $5.0 million in Q3 2025.
Editas Medicine (EDIT) Short term Debt (2024 - 2025) Analysis & Trends
Editas Medicine (EDIT) has 2 years of Short term Debt data on file, last reported at $5.0 million in Q4 2025.
- On a quarterly basis, Short term Debt changed 0.0% year-over-year to $5.0 million in Q4 2025; TTM through Dec 2025 was $5.0 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $5.0 million, changed 0.0% from the prior year.
- Short term Debt for Q4 2025 stood at $5.0 million, roughly flat from $5.0 million in the prior quarter.
- Over the last five years, Short term Debt for EDIT reached as high as $5.0 million in Q4 2024 and fell as low as $5.0 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Editas Medicine | 245.95 Mn | 99.30 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.00 Mn |
| Sep 30, 2025 | 5.00 Mn |
| Jun 30, 2025 | 5.00 Mn |
| Mar 31, 2025 | 5.00 Mn |
| Dec 31, 2024 | 5.00 Mn |